Complications of transplanted kidney – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:30:49 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Complications of transplanted kidney – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on ARGX-117 for Improving Kidney Function in Patients with Delayed Graft Function After Deceased Donor Transplant https://clinicaltrials.eu/trial/study-on-argx-117-for-improving-kidney-function-in-patients-with-delayed-graft-function-after-deceased-donor-transplant/ Wed, 29 Apr 2026 14:26:40 +0000 https://clinicaltrials.eu/trial/study-on-argx-117-for-improving-kidney-function-in-patients-with-delayed-graft-function-after-deceased-donor-transplant/ This clinical trial is focused on studying a condition known as delayed graft function, which can occur in patients who have received a kidney transplant from a deceased donor. This condition means that the new kidney may not start working as quickly as expected after the transplant. The study is testing a treatment called ARGX-117, which is given as an intravenous infusion, meaning it is administered directly into the bloodstream through a vein. The purpose of the study is to see if ARGX-117 can help improve the function of the transplanted kidney in patients who are at risk for delayed graft function.

Participants in the study will be randomly assigned to receive either ARGX-117 or a placebo, which looks like the treatment but does not contain the active substance. The study is designed to be double-blinded, meaning neither the participants nor the researchers will know who is receiving the actual treatment or the placebo. This helps ensure that the results are not influenced by expectations about the treatment. The study will take place over several weeks, with regular check-ups to monitor the health and kidney function of the participants.

The main goal is to assess how well the transplanted kidney is working 24 weeks after the transplant. Other aspects being monitored include the number of participants who experience delayed graft function, the duration of any dialysis treatment needed, and overall safety outcomes. The study will also look at how the body processes ARGX-117 and any potential immune responses to the treatment. The results will help determine if ARGX-117 is a safe and effective option for improving kidney function in transplant recipients at risk for delayed graft function.

]]> Study on Preventing BK Virus Infection in Kidney Transplant Patients Using Mycophenolic Acid, Mycophenolate Mofetil, and Sirolimus https://clinicaltrials.eu/trial/study-on-preventing-bk-virus-infection-in-kidney-transplant-patients-using-mycophenolic-acid-mycophenolate-mofetil-and-sirolimus/ Wed, 29 Apr 2026 14:24:08 +0000 https://clinicaltrials.eu/trial/study-on-preventing-bk-virus-infection-in-kidney-transplant-patients-using-mycophenolic-acid-mycophenolate-mofetil-and-sirolimus/ This clinical trial is focused on preventing viral infections caused by the BK virus after a kidney transplant. The study is examining how the body’s immune system, which is responsible for fighting infections, can be strengthened to protect against this virus. The trial involves patients who have received a kidney transplant and are on specific medications to suppress their immune system, which is necessary to prevent the body from rejecting the new kidney. These medications include tacrolimus, mycophenolate mofetil (also known as CellCept), mycophenolic acid (also known as Myfortic), and sirolimus (also known as Rapamune).

The purpose of the study is to understand how different combinations of these medications affect the immune system’s ability to fight the BK virus. Participants will be monitored for changes in their immune response and viral load, which is the amount of virus present in the blood. The study will also look at how the immune system’s cells, such as T cells and B cells, respond to the virus. This includes examining specific proteins and antibodies that play a role in fighting infections.

Participants in the study will take their prescribed medications and have regular check-ups to monitor their health and immune response. The study will last for up to 16 weeks, during which time researchers will collect and analyze data to better understand how to prevent BK virus infections in kidney transplant patients. The findings from this study could help improve treatment strategies and outcomes for future patients undergoing kidney transplants.

]]>